Sarpogrelate Hydrochloride, a Selective 5-hydroxytryptamine(2A) Antagonist, Augments Autologous Bone Marrow Mononuclear Cell Implantation-induced Improvement in Endothelium-dependent Vasodilation in Patients With Critical Limb Ischemia
Journal of Cardiovascular Pharmacology 55 巻 1 号
56-61 頁
2010-01 発行
アクセス数 : 882 件
ダウンロード数 : 238 件
今月のアクセス数 : 4 件
今月のダウンロード数 : 3 件
この文献の参照には次のURLをご利用ください : https://ir.lib.hiroshima-u.ac.jp/00029247
ファイル情報(添付) |
JCardiovascPharmacol_55_56.pdf
158 KB
種類 :
全文
|
タイトル ( eng ) |
Sarpogrelate Hydrochloride, a Selective 5-hydroxytryptamine(2A) Antagonist, Augments Autologous Bone Marrow Mononuclear Cell Implantation-induced Improvement in Endothelium-dependent Vasodilation in Patients With Critical Limb Ischemia
|
作成者 |
Miyazaki Masanori
Goto Chikara
Sanada Hiroaki
|
収録物名 |
Journal of Cardiovascular Pharmacology
|
巻 | 55 |
号 | 1 |
開始ページ | 56 |
終了ページ | 61 |
抄録 |
Background: The purpose of this study was to determine the effect of a combination of bone marrow mononuclear cell (BM-MNC) implantation and sarpogrelate, a selective 5-HT2A antagonist, on endothelial function in patients with critical limb ischemia (CLI). Methods: We evaluated the leg blood flow (LBF) responses to acetylcholine (ACh) and sodium nitroprusside before and after BM-MNC implantation in 16 patients with CLI. We divided patients with CLI into 2 groups: those cotreated with sarpogrelate orally for 12 weeks (sarpogrelate group, n = 8) and those who remained on conventional therapy (control group, n = 8). LBF was measured by strain gauge plethysmography. Results: BM-MNC implantation improved ankle brachial pressure index, transcutaneous oxygen pressure, and pain-free walking time, There was no significant difference in these parameters between the 2 groups. Before BM-MNC implantation, LBF responses to ACh were similar in the sarpogrelate group and control group. Twelve weeks of BM-MNC implantation enhanced LBF responses to ACh in the sarpogrelate and control groups. After 12 weeks of BM-MNC implantation, LBF response to ACh was significantly greater in the sarpogrelate group than in the control group. BM-MNC implantation did not alter the LBF responses to sodium nitroprusside in either group. Conclusions: These findings suggest that BM-MNC implantation improved not only limb ischemic symptoms but also endothelium-dependent vasodilation in patients with CLI. A combination of BM-MNC implantation and sarpogrelate had a more beneficial effect on vascular function in these patients.
|
著者キーワード |
angiogenesis
cell therapy
endothelial function
limb ischemia
|
NDC分類 |
医学 [ 490 ]
|
言語 |
英語
|
資源タイプ | 学術雑誌論文 |
出版者 |
Lippincott Williams & Wilkins
|
発行日 | 2010-01 |
権利情報 |
Copyright (c) 2010 Lippincott Williams & Wilkins, Inc.
|
出版タイプ | Author’s Original(十分な品質であるとして、著者から正式な査読に提出される版) |
アクセス権 | オープンアクセス |
収録物識別子 |
[ISSN] 0160-2446
[DOI] 10.1097/FJC.0b013e3181c37da4
[NCID] AA00257104
[DOI] http://dx.doi.org/10.1097/FJC.0b013e3181c37da4
|